SEC Comment Letter 0000000000-24-010468 to Silexion Therapeutics Corp (SLXN)
Silexion Therapeutics Corp
Date: Sept. 16, 2024 · CIK: 0002022416 · Accession: 0000000000-24-010468
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-282017
Letter
September 16, 2024 Ilan Hadar Chairman and Chief Executive Officer Silexion Therapeutics Corp 2 Ha’ma’ayan Street Modi’in-Maccabim-Reut, Israel 7177871 Re:Silexion Therapeutics Corp Registration Statement on Form S-1 Filed September 10, 2024 File No. 333-282017 Dear Ilan Hadar: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Gary Emmanuel, Esq.
Show Raw Text
September 16, 2024
Ilan Hadar
Chairman and Chief Executive Officer
Silexion Therapeutics Corp
2 Ha’ma’ayan Street
Modi’in-Maccabim-Reut, Israel 7177871
Re:Silexion Therapeutics Corp
Registration Statement on Form S-1
Filed September 10, 2024
File No. 333-282017
Dear Ilan Hadar:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Gary Emmanuel, Esq.